Leukemia: all 5,475 studies
Page 2 of 55. Open to participants first (629), then studies with results posted, then the rest; newest registration first within each.
- Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms PatientsNot yet recruitingNCT06900088Phase 2
- Gut Health in Children With CancerRecruitingNCT06899581
- Comparison of ATLG and ATG for Immune Reconstitution After Allo-HSCT for Hematologic MalignancyRecruitingNCT06895538Phase 2/3
- Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical TransplantationRecruitingNCT06892223Phase 2
- Clinical Study on the Safety and Efficacy of BiTE-EV in Relapsed/Refractory Acute B-Cell LeukemiaRecruitingNCT06890494Early Phase 1
- JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ LeukemiaRecruitingNCT06890065Not applicable
- Efficacy of Short-course Blinatumomab for MRD Erradication in B-ALLRecruitingNCT06886074Phase 2
- Infusion of Alloreactive nk Cells for Mrd-positive Aml PatientsRecruitingNCT06885476Not applicable
- A Clinical Study to Evaluate the Safety and Efficacy of CLL1 and CD38 Dual-Target CAR-T Cell Injection in the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaRecruitingNCT06880354Phase 1
- A Single-arm, Prospective Study of TBI + BUMEL As a Conditioning Regimen for Salvage HSCT in Patients with R/R AMLRecruitingNCT06879847Not applicable
- The Treatment of Newly Diagnosed CD19+Mixed Phenotype Acute Leukemia in AdultsNot yet recruitingNCT06876701Early Phase 1
- Targeting Acute Myeloid Leukemia Immunosuppressive Microenvironment by combinedIDO1 Inhibition and PD-1 BlockadeRecruitingNCT06874257
- Pre-malignant States to Hematologic Malignancies in FirefightersRecruitingNCT06870760
- Thiotepa Combined With Busulfan and Fludarabine Conditioning Regimen for Haploidentical Hematopoietic Stem Cell Transplantation in Elderly Patients With High-Risk Acute Myeloid LeukemiaRecruitingNCT06869265Phase 2
- CD-19 CAR-T Cell for Pediatric ALL or LymphomaRecruitingNCT06866873Not applicable
- Evaluation of CD47, "Do Not Eat Me" Signal Expression in Chronic Myeloid LeukemiaNot yet recruitingNCT06865443
- A Swiss Assessment of Hypothalamic-pituitary-adrenal Axis Suppression After Glucocorticoid Therapy for Leukemia and Lymphoblastic Lymphoma in ChildrenRecruitingNCT06861530
- Effectiveness and Safety of InO±DLI for Relapsed B-ALL/LBL After Allo-HSCTNot yet recruitingNCT06861348Phase 2
- Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell TransplantRecruitingNCT06856226
- Effectiveness of Early Intervention in Palliative Care for Acute Myeloid Leukemia Patients Comparing to Standard of CareNot yet recruitingNCT06848270Not applicable
- Safely Delivered Targeted High-dose Irradiation Followed by Adoptive Immunotherapy with Regulatory and Conventional T Cells to Increase Potency of Hematopoietic Stem Cell Transplantation in High-risk Acute LeukemiaRecruitingNCT06845592Not applicable
- Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCTRecruitingNCT06839456Phase 1/2
- CD123-CD16-NK Cells Immunotherapy for AMLRecruitingNCT06835140Phase 1
- CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and LymphomaRecruitingNCT06834529Phase 1/2
- Study to Evaluate the Safety and Efficacy of ARI0002h, for the Initial Treatment of Patients With Primary Plasma Cell LeukaemiaNot yet recruitingNCT06830733Phase 2
- Veneclax, Chidaniline Combined With Azacitidine Followed by Decitabine + MAG Regimen in the Treatment of Elderly Untreated AMLRecruitingNCT06827899Phase 2
- Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete RemissionRecruitingNCT06824168Phase 2
- Study of the Immunological Infiltrate and Immunometabolic Immunometabolic Profile of Patients with Acute LeukaemiaRecruitingNCT06814444
- Clonal Dynamics of Chronic Lymphocytic Leukaemia Treated With Pirtobrutinib After Previous Treatment With ZanubrutinibRecruitingNCT06812715Phase 2
- HVA vs IA/DA or VA in the Treatment of ND HR-AMLRecruitingNCT06810791Phase 3
- Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)RecruitingNCT06810778Phase 1/2
- A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk LeukemiaRecruitingNCT06810583Phase 1
- Interferon-alpha As Maintenance Therapy for Favorable-risk Acute Myeloid LeukemiaRecruitingNCT06802718Phase 3
- Tumors and Respiratory System Diseases Due to Air Pollution: New Biomarkers of Exposure and EffectsRecruitingNCT06800586
- Epidemiology of Infection in Acute Myeloid Leukemia (AML)Not yet recruitingNCT06797648
- The Implementation of the Go Wish Game to Promote Advance Care Planning in Onco- Hematologic DiseaseRecruitingNCT06795815Not applicable
- Donor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic LeukemiaRecruitingNCT06793241Early Phase 1
- A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing SettingRecruitingNCT06788639
- Clinical Study on the Safety and Efficacy of Autologous CD84 Chimeric Antigen Receptor T-Cell Therapy for Adult Relapsed/Refractory Acute Myeloid Leukemia.Not yet recruitingNCT06786299Early Phase 1
- Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL)RecruitingNCT06785324Not applicable
- Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCTRecruitingNCT06783790Phase 2
- NK Cell Infusion for Remission Consolidation in AML: A Phase II TrialNot yet recruitingNCT06783478Phase 2
- Assessment of Disease Burden in Hairy Cell LeukemiaRecruitingNCT06781515Not applicable
- Oral-ATO for TP53-mutated Myeloid MalignanciesRecruitingNCT06778187Phase 2
- Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for Newly Diagnosed B-cell ALL Patients in CR1Not yet recruitingNCT06777264Phase 2
- Decoding the Extracellular Vesicles-driven Communication in the Microenvironment of Hairy Cell Leukemia to Improve Patient Care ManagementRecruitingNCT06774677
- Hairy Cell Leukemia: Harnessing the Full Power of Extracellular Vesicles to Improve Patient Care ManagementRecruitingNCT06764524
- Molecular Characterization of Patients With Acute Myeloid Leukemia and the Impact of Clonal Evolution in the Response to Therapeutic TreatmentsRecruitingNCT06764459
- A Clinical Study to Explore the Safety and Efficacy of CD33 CAR-T Cell in Relapsed/Refractory Acute Myeloid LeukemiaRecruitingNCT06762132Early Phase 1
- Evaluation of the Safety and Efficacy of Human CI-135 (FLT3) Targeted CAR-T Cells Injection for Subjects with Relapsed/Refractory Acute Myeloid LeukemiaRecruitingNCT06760260Early Phase 1
- Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with HemoblastosisRecruitingNCT06756152Phase 2/3
- Azacitidine Combined with Donor Lymphocyte Infusion for Acute Myeloid Leukemia Post-transplant Relapse Prevention.Not yet recruitingNCT06754540Phase 2
- Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALLRecruitingNCT06754267Phase 2
- CD19/CD22 CAR-T Cell Therapy in MRD-Positive B-lineage Acute Lymphoblastic Leukemia in Children.RecruitingNCT06752785Phase 1
- Role of Cbc Indices in Acute Lymphoblastic Leukemia PatientsNot yet recruitingNCT06746571Not applicable
- BN104 in Combination With Chemotherapy or Targeted Agents for Acute Myeloid LeukemiaRecruitingNCT06746519Phase 1/2
- VHAG in Treating R/R T-ALL/LBLRecruitingNCT06742463Phase 2
- Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AMLRecruitingNCT06741722Phase 2
- Chiglitazar Sodium Combined With Venetoclax and Azacitidine (CVA) for the Treatment of R/R AMLRecruitingNCT06737523Phase 1
- Interaction Between Gut Microbiota and TKIs in Defining the Clinical Outcomes of Patients With CMLRecruitingNCT06724536
- Virtual Reality During Lumbar Punctures in Acute Lymphoblastic LeukemiaRecruitingNCT06722638Not applicable
- a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell LeukemiaRecruitingNCT06718270Early Phase 1
- Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1RecruitingNCT06718244Phase 2
- Induced Pluripotent Stem Cells Derived Natural Killer Cells Therapy for Refractory and Relaps Acute Myelogenous LeukemiaNot yet recruitingNCT06702098Early Phase 1
- Daunorubicin + Cytarabine + Venetoclax in de Novo AMLEnrolling by invitationNCT06697327Not applicable
- Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic LeukemiaRecruitingNCT06696833Early Phase 1
- Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive TreatmentRecruitingNCT06696183Phase 2
- Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse PreventionRecruitingNCT06686108Phase 2
- Atorvaststin and Cardiotoxicity in Acute Myloid LeukemiaNot yet recruitingNCT06684509Phase 1/2
- Systemic Inflammation Response Index and C-Reactive Protein to Albumin Ratio in Acute Lymphoblastic LeukemiaNot yet recruitingNCT06674850
- BuCy Vs. TBICy for Allo-HSCT in T-ALL PatientsNot yet recruitingNCT06673459Phase 3
- A Clinical Trial to Evaluate the Safety and Tolerability of TQB3911 Tablets in Patients With BCR::ABL Fusion Gene Positive LeukemiaNot yet recruitingNCT06672263Phase 1
- The Prognostic Role of Fibrinogen to Albumin Ratio in Acute Leukemia PatientsNot yet recruitingNCT06668948
- Efficacy of Gilteritinib in Combination With FLAI as Induction Therapy of FLT3-positive Acute Myeloid LeukemiaNot yet recruitingNCT06667973Phase 2
- Olverembatinib as Maintenance Therapy or Preemptive Therapy After Allo-HSCT in Ph+ALLNot yet recruitingNCT06658925Phase 2
- An Exploratory Study of RD140 Injection in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell LeukemiaNot yet recruitingNCT06655519Phase 1
- Effects of a Strength Physical Exercise Program in Chronic Lymphocytic Leukemia PatientsNot yet recruitingNCT06654206Early Phase 1
- Molecular Subtype Combined with Early Minimal Residual Disease to Optimize the Treatment of Newly Diagnosed Acute Myeloid LeukemiaNot yet recruitingNCT06652685Phase 2
- Dose-escalation Study of D-CMG Regimen for the Treatment of Elderly Newly Diagnosed AML PatientsRecruitingNCT06651866Phase 1
- Childhood B-acute Lymphoblastic Leukaemia and Role of CD9 Gene Regulation in RelapseRecruitingNCT06649253Not applicable
- Long-term Risk of Second Primary Malignancies for Chronic Myeloid Leukaemia in the French Imatinib-based SPIRIT TrialEnrolling by invitationNCT06646978
- Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)RecruitingNCT06644183Phase 1/2
- Venetoclax Combined with Intensive Therapy for Acute Myeloid Leukemia Patients with Lower Early Peripheral Blast Clearance Rate After Standard Induction TherapyRecruitingNCT06643962Not applicable
- Exercise as an Immune Adjuvant for Allogeneic Cell TherapiesRecruitingNCT06643221Early Phase 1
- Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Re-treatment for Patients With High-Risk Acute Myeloid LeukemiaNot yet recruitingNCT06643195Not applicable
- EX02 CAR-T Cells for Relapsed and Refractory Acute Myeloid LeukemiaRecruitingNCT06642025Early Phase 1
- Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/ Refractory B-ALLNot yet recruitingNCT06641024Phase 1
- An Investigator-Initiated, Phase II, Multicenter, Open-Label, Single-Arm, Prospective Clinical Trial to Evaluate the Efficacy and Safety of Alternating Bortezomib-Based Regimens in Combination With DaratUMumab Followed by Maintenance With Daratumumab in the Frontline Setting of Primary Plasma CEll LRecruitingNCT06636552Phase 2
- Safety and Efficacy of CAR T Cell Therapy in Patients with R/r B-ALLRecruitingNCT06635330Phase 1/2
- APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AMLRecruitingNCT06634394Phase 1
- Jacobson's Progressive Muscle Relaxation Technique on Children With Leukemia Undergoing Chemotherapy.Not yet recruitingNCT06631196Not applicable
- Cell Therapy with Anti-CD19 CAR-NK Cells in Patients with Relapsed or Resistant B-ALLNot yet recruitingNCT06631040Phase 1/2
- Integrative "Omics" Approaches for Leukemia Target Identification and Matched Therapeutic InterventionRecruitingNCT06626893Not applicable
- Twice-per-weekSelinexor, 2 Days MelphalanNot yet recruitingNCT06613035Phase 3
- Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission.RecruitingNCT06608732Phase 2
- Autologous Hematopoietic Stem Cell Transplantation Combined With CD19-CART Treatment of Adult High-risk Acute Lymphoblastic LeukemiaRecruitingNCT06608342Phase 2
- Efficacy Study of Blinatumomab Clean Up Early Residual Disease for Newly Diagnosed Pediatric B Lymphoblastic LeukemiaRecruitingNCT06607419Phase 2/3
- TMLI/Fludarabine/Melphalan Conditioning for Allogeneic Transplantation in High-risk Myelodysplastic Syndrome or Acute Myeloid Leukemia.Not yet recruitingNCT06602323Phase 2
- TMLI Plus Chemotherapy in High Risk Myelodysplastic Syndrome or Acute Myeloid LeukemiaNot yet recruitingNCT06598969Phase 2
- BCL-2 Inhibitors Combined with the HyperCVAD Regimen for Newly Diagnosed T-lymphoblastic Leukemia/lymphoma.RecruitingNCT06598722Phase 2